ATE302416T1 - Auf holo-transcobalamin ii beruhendes diagnostisches verfahren für alzheimer-krankheit - Google Patents

Auf holo-transcobalamin ii beruhendes diagnostisches verfahren für alzheimer-krankheit

Info

Publication number
ATE302416T1
ATE302416T1 AT01931928T AT01931928T ATE302416T1 AT E302416 T1 ATE302416 T1 AT E302416T1 AT 01931928 T AT01931928 T AT 01931928T AT 01931928 T AT01931928 T AT 01931928T AT E302416 T1 ATE302416 T1 AT E302416T1
Authority
AT
Austria
Prior art keywords
holo
alzheimer
transcobalamin
diagnostic method
disease based
Prior art date
Application number
AT01931928T
Other languages
English (en)
Inventor
Lars Oerning
Original Assignee
Axis Shield Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axis Shield Asa filed Critical Axis Shield Asa
Application granted granted Critical
Publication of ATE302416T1 publication Critical patent/ATE302416T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01931928T 2000-07-04 2001-05-22 Auf holo-transcobalamin ii beruhendes diagnostisches verfahren für alzheimer-krankheit ATE302416T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0016460.8A GB0016460D0 (en) 2000-07-04 2000-07-04 Assay
PCT/GB2001/002306 WO2002003074A1 (en) 2000-07-04 2001-05-22 Diagnostic method for alzheimer's disease based on holo-transcobalamin ii

Publications (1)

Publication Number Publication Date
ATE302416T1 true ATE302416T1 (de) 2005-09-15

Family

ID=9895035

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01931928T ATE302416T1 (de) 2000-07-04 2001-05-22 Auf holo-transcobalamin ii beruhendes diagnostisches verfahren für alzheimer-krankheit

Country Status (11)

Country Link
US (1) US7294514B2 (de)
EP (1) EP1297342B1 (de)
JP (1) JP2004502940A (de)
AT (1) ATE302416T1 (de)
AU (1) AU2001258614A1 (de)
DE (1) DE60112758T2 (de)
DK (1) DK1297342T3 (de)
ES (1) ES2249432T3 (de)
GB (1) GB0016460D0 (de)
PT (1) PT1297342E (de)
WO (1) WO2002003074A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150065449A1 (en) 2011-08-12 2015-03-05 Florida State University Research Foundation, Inc. Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG
WO2018188771A1 (en) * 2017-04-11 2018-10-18 Nestec S.A. Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
MX2019010484A (es) * 2017-04-11 2019-10-17 Nestle Sa Niveles de acidos grasos omega-3 y vitamina d para identificar y atenuar el envejecimiento congnitivo en individuos.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4273757A (en) * 1977-06-02 1981-06-16 Yissum Research Development Company Determination of transcobalamins
US4680273A (en) * 1985-07-29 1987-07-14 Victor Herbert Assay for vitamin B12 deficiency
EP1105739A1 (de) * 1998-08-20 2001-06-13 Axis-Shield Asa Diagnoseverfahren für kardiovaskuläre erkrankungen
GB9820473D0 (en) * 1998-09-18 1998-11-11 Axis Biochemicals Asa Assay

Also Published As

Publication number Publication date
ES2249432T3 (es) 2006-04-01
PT1297342E (pt) 2005-10-31
DE60112758D1 (de) 2005-09-22
US20040014230A1 (en) 2004-01-22
EP1297342B1 (de) 2005-08-17
JP2004502940A (ja) 2004-01-29
EP1297342A1 (de) 2003-04-02
GB0016460D0 (en) 2000-08-23
WO2002003074A1 (en) 2002-01-10
US7294514B2 (en) 2007-11-13
DE60112758T2 (de) 2006-06-29
DK1297342T3 (da) 2005-12-19
AU2001258614A1 (en) 2002-01-14

Similar Documents

Publication Publication Date Title
DE69928809D1 (de) Differentielle diagnose von neurodegeneration
DE60016178D1 (de) Verfahren zur diagnose und zur charakterisierung von schlaganfall
DK2275815T3 (da) Forbedrede immunoassay-fremgangsmåder
ATE351921T1 (de) Verfahren für fluoreszenzerkennungstest
EP2120226A3 (de) Gereiste-Verbindung Identifizierungssystem
BR0206604A (pt) Dispositivo de lanceta que tem ação capilar
ATE337413T1 (de) Methoden zur verbesserung der sensitivität und spezifität von screeningverfahren für krebs und krebs-vorstufen
ATE331960T1 (de) Diagnose von myokardinfarkt und akutem koronarsyndrom durch kombination von markern
ATE314354T1 (de) Radiopharmazeutika für die diagnose von alzheimer
ATE422671T1 (de) Verfahren zur diagnose von morbus alzheimer
ATE424560T1 (de) Marker für neuromyelitis optica
DE69929785D1 (de) Verfahren zur Diagnose, Erkennung, und Einstufung von Dickdarmkrebs
ATE282831T1 (de) Verfahren zur diagnose von sepsis unter bestimmung löslicher cytokeratinfragmente
ATE343597T1 (de) Diagnostisches assay für typ-2-heparin induzierte thrombocytopenie
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
DE60112758D1 (de) Auf holo-transcobalamin ii beruhendes diagnostisches verfahren für alzheimer-krankheit
DE50007635D1 (de) Verfahren zur diagnose von sjögren-syndrom
DE60036935D1 (de) Diagnostisches Verfahren für Eierstock- und Endometriumtumore basierend auf dem Nachweis des L1-Adhäsionsmoleküls
ES2126151T3 (es) Metodo para cuantificar bpi extracelular en fluidos corporales.
BR9913770A (pt) Processo de ensaio para determinação da cobalamina ligada a transcobalamina ii (tcii) em uma amostra de corpo, kit para uso em um ensaio diagnóstico, e, uso de holo-tc ii
BR0007702A (pt) Método e kit de diagnóstico para diagnose de endometriose
ATE406579T1 (de) Verfahren zur diagnose von tumoren
ATE459877T1 (de) Diagnostikum für die frühe phase von morbus alzheimer
BRPI0415562A (pt) reagente para avaliação diagnóstica e/ou prognóstica de carcinoma, métodos para determinação de p-lap que é um fator prognóstico em carcinoma, e para avaliação prognóstica de carcinoma, e, kit de imunoensaio para determinação da quantidade de p-lap presente em tecidos de carcinoma
DE69912453D1 (de) Verfahren und materialien zur diagnose instabiler angina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1297342

Country of ref document: EP

REN Ceased due to non-payment of the annual fee